Related Experiment Video
Updated: Jan 19, 2026

Motor Dual-Tasks for Gait Analysis and Evaluation in Post-Stroke Patients
Published on: March 11, 2021
Update on Dual Antiplatelet Therapy for Secondary Stroke Prevention
Alexandria Stringberg1, Ryan Camden1, Kathryn Qualls1
1Alexandria Stringberg, Pharmd, PGY2 Internal Medicine Pharmacy resident; Ryan Camden, PharmD, BCPS, Clinical Pharmacy Specialist - Internal Medicine, PGY-2 Internal Medicine Residency Program Director; Kathryn Qualls, PharmD, BCPS, BCCCP, Clinical Pharmacy Specialist-Neurology; and Syed H. Naqvi, MD, Associate Professor of Clinical Medicine, Division of Hospital Medicine; all at the University of Missouri Health System.
Insights
Dual antiplatelet therapy with aspirin and clopidogrel may aid secondary stroke prevention after minor stroke or transient ischemic attack. However, the exact bleeding risk associated with this treatment strategy requires further investigation.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Pharmacology
Background:
- Aspirin is a standard treatment for acute ischemic stroke.
- Dual antiplatelet therapy (DAPT) shows potential for early secondary stroke prevention.
- The safety profile of DAPT, particularly bleeding risk, needs clarification.
Purpose of the Study:
- To review existing literature on DAPT for secondary stroke prevention.
- To evaluate the benefits of DAPT in minor stroke and transient ischemic attack (TIA).
- To analyze the risk-benefit balance of DAPT in this patient population.
Main Methods:
- Literature review of published studies.
- Analysis of clinical trials and observational data.
- Focus on studies investigating aspirin and clopidogrel combination therapy.
Main Results:
- DAPT may offer benefits in secondary prevention for minor stroke/TIA patients.
- The precise bleeding risk associated with DAPT remains uncertain.
- Balancing therapeutic benefits against potential bleeding complications is crucial.
Conclusions:
- DAPT (aspirin and clopidogrel) is a potential strategy for secondary stroke prevention.
- Further research is needed to precisely quantify bleeding risks.
- Individualized treatment decisions should weigh the benefits against the risks.
Abstract:
Aspirin is recommended for patients with acute ischemic stroke within 24 hours of symptom onset. It may be beneficial for dual antiplatelet therapy including clopidogrel and aspirin to be administered in patients with minor stroke or transient ischemic attack for early secondary prevention, however, bleeding risk remains uncertain. This article will review the published literature concerning the role of dual antiplatelet therapy for secondary stroke prevention with focus on balancing both risk and benefit.
More Related Videos
Related Concept Videos
05:23Motor Dual-Tasks for Gait Analysis and Evaluation in Post-Stroke Patients
07:42Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
13:44Haptic/Graphic Rehabilitation: Integrating a Robot into a Virtual Environment Library and Applying it to Stroke Therapy
10:45The Mouse Stroke Unit Protocol with Standardized Neurological Scoring for Translational Mouse Stroke Studies
Secondary Active Transport

